GLP-1 receptor agonists slow clinical progression of Alzheimer's disease.
- Current status
- Not supportedEvidence weakening · Alzheimers
- Why
- Two adequately powered phase 3 trials (evoke, evoke+) were negative on the primary clinical endpoint; ELAD phase 2b was negative on its primary endpoint.
- What would change it
- A new randomized trial with a different agent, earlier stage, or a biologically enriched subgroup showing a clinically meaningful CDR-SB difference.
- Linked studies
- 2 · 1 contradicts · 1 mixed
- Last updated
- Sep 13, 2026
The status is the collection's own judgment on its assessment scale, not a GRADE certainty rating and not medical advice.
01The evidence
The evidence, sorted by what it shows
Contradicts (1)
- Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trialsRandomized trial · 2026 · Study tier 1 · Partial match · Null · Industry funded
Primary clinical endpoint null in both trials.
Mixed (1)
- Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trialRandomized trial · 2026 · Study tier 3 · Partial match · Mixed · Partly industry funded
Primary imaging endpoint null; small secondary signal.
02History
How this assessment has changed
- Not supportedSep 13, 2026 · Evidence weakening
initial curated status